In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pearl Therapeutics, Inc.

http://www.pearltherapeutics.com/

Latest From Pearl Therapeutics, Inc.

FDA Idea To ‘Encourage Competition For New Drugs’ Spares Cutting OTC Switch Market Exclusivity

“FDA is seeking to encourage competition for new drugs by proposing to amend the Hatch-Waxman 3-year exclusivity provisions to ensure that this exclusivity is limited to situations where the new drug applicant is actually seeking such exclusivity,” according to legislative proposals document.

Prescription To OTC Switch FDA

Stock Watch: Pharma Businesses That Leave Consumer Behind

Healthcare conglomerates that divorce consumer, animal health and even generics businesses from their pure-play branded pharmaceutical groups could leave a less diversified and riskier sector in uncertain times. But the advantages are apparent.

Stock Watch Consumer

Finance Watch: Obsidian’s $160.5m Financings Comes In A Flurry Of VC Mega-Rounds

Private Company Edition: Three consecutive $100m-plus venture capital rounds include Obsidian’s series C, a $132m series B round for Alterome and Diagonal’s $128m launch. Also, The Medicines Company’s Clive Meanwell reportedly is heading up a well-founded obesity start-up.

Financing Innovation

Finance Watch: Pfizer Adds $3.5bn To Cash Stockpile, Reduces Stake In Haleon

Public Company Edition: Pfizer’s stake in Haleon dropped from 32% to 22.6% with a massive sale of shares of the GSK consumer health spinout. Also, Galderma prices its Swiss IPO, Madrigal grosses $600m in a post-approval offering and bluebird secured up to $175m in debt.

Financing Growth
See All

Company Information

UsernamePublicRestriction

Register